The analysis of sequences in the 5ʹ upstream region of STC2, a gene known to promote prostate cancer proliferation, revealed that the combination treatment induced at least a slight increase in DNA methylation (40%) compared with the controls (35%) (Figure 5A). The gene discussed is STC2; the disease is prostate cancer.